In the last decade the nephrology community has learned much about the impact of anemia
on patients with kidney disease. Therapy of anemia can correct many of the symptoms which …

Anemia management remains controversial in patients with chronic kidney disease (CKD).
The overwhelming conclusion from retrospective data analyses show a strong correlation …

The introduction of recombinant human erythropoietin treatment has been one of the most
important advances in the treatment of dialysis patients and others with chronic kidney …

Even though anemia occurs frequently in patients with chronic kidney disease and
therapeutic options are widely available, the ideal hemoglobin target level is not clearly …

Since the introduction of erythropoiesis-stimulating agents (ESAs) into clinical practice in
1989, considerable effort has been put forth toward identifying the optimal treatment strategy …

Recombinant human erythropoietin (rHuEPO, epoetin) revolutionized the treatment of
anemia in patients with chronic kidney disease (CKD) when it was approved for use in the …

The morbidity, mortality and economic burden of chronic kidney disease (CKD) and
associated anaemia are substantial. With the increasing numbers of patients who are likely …

Renal anemia is caused by the deficiency of endogenous erythropoietin (Epo) due to renal
dysfunction. We think that it is possible to slow the progression of chronic kidney disease …

Despite the publication of National Kidney Foundation and European Best Practice
Guidelines, there is still uncertainty among nephrologists regarding the optimum target …

Introduction Several anemia guidelines for hemodialysis patients have recommended a
target hemoglobin (Hb) range of 10–12 g/dL. However, maintaining Hb values continuously …